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The potential of monoclonal antibodies for radioimmunotherapy has been recognised for some time but so far clinical success with radioimmunotherapy has been limited. Attempts at radioimmunotherapy of colon carcinoma have been reported with antibodies radiolabelled with a variety of isotopes including '3'Iodine and 90Yttrium (reviewed by Mach et al., 1991) . Most therapeutic studies to date have been carried out with the medium energy (0.6 MeV) beta emitter '3', as antibody labelling with this radionuclide is relatively straightforward and the gamma emission also allows imaging and quantitative biodistribution studies to be carried out in man. The radionuclide 90Y is an attractive alternative to "3'I owing to its physical properties as a short half-life, highenergy pure beta emitter (2.3 MeV), which conveys potential advantages not only in terms of energy deposited but in patient handling. Early studies with 90Y-labelled antibodies were limited however, owing to the instability of 90Y complexes with conventional chelators such as DTPA. The use of radiometals as therapeutic agents is dependent on the development of chelators that can hold them with high stability under physiological conditions. This is particularly true for 90Y which forms deposits in bone if leakage from a chelator takes place resulting in unacceptable toxicity; (Washburn et al., 1988) . Recently, macrocyclic bifunctional chelating agents have been developed which consist of a moiety for attachment to antibody and a macrocyclic metal chelator (Cox et al., 1989; Moi et al., 1990) . These agents form a stable linkage betwen monoclonal antibody and 90Y and favourable biodistributions with antibodies labelled with 90Y via these macrocyclic chelators have been reported (Harrison et al., 1991; DeNardo et al., 1994; King et al., 1994) .
Several studies on the therapeutic efficacy in mouse models of monoclonal antibodies labelled with 90Y via acyclic chelators such as DTPA have been reported previously (Hyams et al., 1989; Lee et al., 1990; Washburn et al., 1991; Buras et al., 1993) . In these studies growth delay of colorectal carcinoma xenografts and improved survival of mice were demonstrated. Therapeutic studies with monoclonal antibodies labelled with 9Y via macrocyclic ligands have not been reported previously.
The monoclonal antibody A33 recognises a tumourassociated antigen on human colorectal carcinoma, and has undergone preliminary evaluation in the clinic where selective localisation to hepatic metastases has been demonstrated (Welt et al., 1990 (Welt et al., , 1994 . The antigen recognised by A33 is restricted to colon cancer and normal colon epithelium and is not related to blood group antigens or other known antigens expressed on colon cancer. Antigen expression in colon cancer is homogeneous and the antigen is not shed into circulation (Welt et al., 1990) .
The success of antibodies for radioimmunotherapy has been limited in part by the associated bone marrow toxicity of radiolabelled antibodies due largely to circulating activity (Badger, 1990; Siegal et al., 1990) . Several approaches are possible in attempts to overcome this problem with A33 including the use of very short-range isotopes such as "25I which are relatively non-toxic to bone marrow (Barendswaard et al., 1993) , and the use of antibody fragments which clear from the circulation more rapidly (King et al., 1994) .
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Here we report an investigation of the therapeutic potential of A33 labelled with 90Y. A33 labelled with 90Y through a macrocyclic ligand has been prepared and its biodistribution and therapeutic efficacy in a colon carcinoma xenograft model established. We have also examined the biodistribution and therapeutic efficacy of a site-specifically labelled tri-Fab fragment of A33 cross-linked with a trimaleimide cross-linker (termed TFM). TFM has several potential advantages over conventional antibody fragments such as Fab and F(ab')2 particularly in terms of improved tumour targeting and no accumulation of 90Y in the kidney (King et al., 1994) .
Materials and methods
Preparation and radiolabelling of immunoconjugates A33 IgG was purified from hybridoma culture supernatant using protein A Sepharose chromatography (Colcher et al., 1989) . A33 IgG conjugates and TFM were prepared under metal-free conditions to minimise any contamination of the macrocycle before labelling.
A33 IgG conjugates were prepared by thiolation of the antibody followed by attachment of the 12N4(DOTA)-maleimide reagent, CT77 (Cox et al., 1989; Harrison et al., 1991) . A33 was dialysed into 0.1 M phosphate buffer, pH 8.0, containing 2 mM DTPA, and concentrated to approximately 10 mg ml-'. A 3-fold molar excess of 2-iminothiolane was added and the reaction incubated at room temperature for 1 h. The thiolated antibody was rapidly desalted to remove excess 2-iminothiolane using a Sephadex G-25 column (PD1O, Pharmacia) into 0.1 M phosphate buffer, pH 6.0, containing 2 mM DTPA and the degree of thiolation achieved determined by titration with dithiodipyridine as described previously (Lyons et al., 1990) . The 12N4-maleimide reagent was then added at a 3-fold molar excess over the thiol concentration and the antibody incubated for 2 h at room temperature. The resulting conjugate was then desalted into 0.1 M potassium acetate buffer, pH 6, for radiolabelling.
To prepare A33 TFM the antibody was initially digested with pepsin to produce F(ab')2 which was then selectively reduced to Fab' and cross-linked to TFM using the trimaleimide linker, CT998 (King et al., 1994) . IgG was dialysed into 0.2 M acetate buffer, pH 4.2, containing 0.5 M ammonium sulphate and concentrated to approximately 10 mg ml-' by ultrafiltration. Pepsin was added to the antibody to a ratio of 1: 50 (w/w) and allowed to digest for 4 h at 37°C. The F(ab')2 produced was then dialysed into 0.1 M Tris-HCl, pH 7.5, and purified by ion-exchange purification using Q-Sepharose (HiLoad column, Pharmacia) with elution by a gradient of 0-0.5 M sodium chloride in 0.1 M Tris-HCl, pH 7.5. As very pure material is required for cross-linking, the F(ab')2 was purified further by gel filtration using Sephacryl S-200HR run in 0.1 M potassium acetate, pH 6.0, containing 2 mM DTPA and 0.1 M potassium chloride.
The purified F(ab')2 was diafiltered into 0.1 M sodium phosphate, pH 8.0, containing 2 mM DTPA and concentrated to 10-15 mg ml-'. Selective reduction was then carried out by incubation with 20 mM 2-mercaptoethylamine at 37°C for 30 min. The reduced material was desalted into 0.1 M sodium phosphate buffer, pH 6.9 containing 2 mM DTPA and the extent of reduction to Fab' checked by gel filtration high performance liquid chromatography (HPLC). The freshly reduced, desalted Fab' was cross-linked to TFM by the addition of CT998 (King et al., 1994) (Richman and Bodmer, 1988) . Therapeutic efficacy of 9Y-labelled A33 IgG and TFM was tested in mice bearing 2-week-old SW1222 xenografts of 0.1-0.2 cm3 in volume. The size of tumours in individual groups is indicated in the Results section. Two weeks after tumour transplantation mice were divided randomly into groups of six. Mice were weighed and the volume of the tumour was measured with calipers before administration of the radiolabelled antibody and twice weekly thereafter.
Tumour volume was calculated using V=4/3n.rIr2r3, where ri, r2 and r3 are the radii of the tumour measured in each dimension. On days 6, 13, 23, 30 and 41 after treatment, mice were bled via the tail vein and the white blood cell count determined using a Coulter counter. A biodistribution study at 24 h was also carried out in groups of four mice with the same labelled antibody preparations used for therapy.
For autoradiography studies nu/nu mice bearing 2-weekold SW1222 tumour xenografts were injected i.v. with 20 uCi (5 jug) of 1251-labelled immunoconjugates. Mice were killed at appropriate times and tumours removed and fixed in 10% formalin for 24 h. Tumours were processed as for routine histology and 6 tm tumour sections cut and mounted on glass slides subbed in 0.25% gelatin solution. The sections were air dried overnight at 37°C. After dewaxing in histoclear Radioimmunotherapy with 90Y A33 IgG and TFM P Antoniw et a! 515 the slides were taken through graded alcohols to distilled water and dipped in a K2 Ilford nuclear emulsion diluted 1:1 in water preheated to 42°C. The slides were air dried for several hours, placed in dark boxes and left at 4°C for 2 weeks. Slides were developed at 20°C by firstly placing in Kodak D-19 developer for 4 min, then removed, placed in 1% solution of glacial acetic acid for 2 min and transferred to fixative (Ilford Hypam) for 6 min. After washing with water for 20 min they were dehydrated and counterstained with haemotoxylin and eosin.
Results

Biodistribution of 9Y-A33 IgG and TFM
The biodistribution of 9Y-labelled A33 IgG in mice demonstrated high levels of activity localised to the tumour xenograft with little or no accumulation in normal tissues ( Figure la) . Tumour levels reached a maximum of 35.9+5.25% injected dose per gram by 48 h after injection which was maintained at 144 h. Low bone levels of activity were observed which decreased with time demonstrating the high level of stability of the macrocycle-9Y complex as has been reported previously (Harrison et al., 1991; De Nardo et al., 1994) .
The biodistribution of 9Y-labelled TFM revealed a much faster rate of blood clearance although it has a similar molecular mass to the IgG (Figure lb) . The maximum level measured in the tumour was 12.9+4.60% injected dose per gram at 24 h after injection. This level was maintained up to 72 h despite the fast clearance of the TFM from the blood. Normal tissues with notable conjugate levels were liver, spleen and kidney, suggesting these are the organs of clearance. However, accumulation was not observed in any of the above tissues, the TFM clearing from all of these with b 91% r ĩ~~~~~~~~~~~~~. (Figure  4c ). All of these animals remained tumour free for 10 months. After this time the mice were killed and the sites of tumour implantation removed for histological examination. All of the sites contained mostly fibrotic and necrotic tissues. There were also some small pocketes of apparently nonproliferating tumour cells. The toxicity of the 9Y-labelled conjugates was evaluated by survival, body weight and white blood cell count. In all cases mice were killed when their tumours reached >2 cm3, in accordance with Home Office guidelines. All mice in the untreated group survived until being killed between 13 and 37 days after treatment, as did the 9°Y-MOPC21-treated mice which were killed between 46 and 72 days after treatment. Only one mouse in the 9Y-A33-treated group suffered severe weight loss by day 20 after treatment (>20% of body weight on day 0) and was thus killed in accordance with the guidelines of the UK Co-ordinating Committee for Cancer Research (welfare of animals in experimental neoplasia). Toxicity was probably caused by bone marrow effects as this particular mouse showed the largest decrease in blood cell count of the group. The remaining mice survived until killed at 10 months as described above. There was no significant weight loss in any of the other treated mice compared with the control group (Figure 5a ). The first white blood cell count was determined on day 6 by which day the count was significantly lower in both groups treated with 90Y-labelled conjugates (Figure 5b) . The white blood cell count in the mice treated with 9°Y-A33 showed a nadir on day 13 at which time it was 423 per mm3 (8.4% of the mean of the control group). By day 23 the white blood cell count had increased to the same levels as the MOPC21-treated group but from then on it recovered at a slower rate. In this experiment it thus appeared that 9Y-labelled A33 was more toxic to the bone marrow than 9Y-MOPC21.
Experiments were then carried out to examine therapeutic effects with 9Y-A33 TFM at a similar ,uCi dose. In the first experiment a dose of 220 LCi was tested and in the second experiment a dose of 300 ,uCi. A non-specific TFM was not available so in these experiments comparisons were made with untreated mice alone.
A Figure 9 . Control animals showed rapid tumour growth as expected (Figure 9a (Figure 9c ). The nadir white blood cell count in this case was reduced to 60% of the control value after 6 days ( Figure 8) . Similarly, when treated with 87 ,Ci 9Y-A33 IgG, a dose equivalent in tumour dose to 300 ,uCi 9°Y-A33 TFM, a mean tumour growth delay and regression time of 32 days was observed before regrowth took place in all animals ( Figure 9d ). This is clearly a less potent anti-tumour effect than seen with 300 pCi 9°Y-A33 TFM where complete regressions were observed in five out of six mice treated.
Discussion
The inability of radiolabelled antibodies to reach their target tumour in adequate quantities has been a major factor limiting their efficacy in cancer treatment. Once they reach the target organ the antibodies must be distributed, transported across the microvasculature wall and through the interstitial spaces (Jain, 1989) . A number of these criteria are determined not only by the morphology and properties of the tumour itself but also by the properties of the chosen antibody and its antigen distribution and expression. (Boxer et al., 1994) . The difference in the distribution of the two antibodies within the tumour is quite distinct in spite of the fact that immunohistochemistry has shown a similar pattern of reactivity between A5B7 and A33 in colon cancer tissue (Boxer et al., 1994) . B72.3 also demonstrated only limited penetration into the xenograft tumour tissue.
Although autoradiography experiments were non-quantitative, detailed examination of the tissues allowed preliminary conclusions to be drawn. A33 IgG penetrated tumour tissue extremely effectively and the derived A33 TFM appeared to penetrate even more rapidly with a more homogeneous distribution at 3 h. This may be significant for radioimmunotherapy with short half-life isotopes as much of the tumour dose is delivered at early times (Yorke et al., 1991 Days after injection more rapid penetration of TFM is unexpected and suggests that other properties of the molecule such as shape, charge or flexibility may also be important in achieving rapid penetration.
The overall biodistribution of 9°Y-A33 demonstrated localisation to tumour with levels accumulating up to 35.9 + 5.25% ID g ' at 144 h after antibody injection. 90Y-A33 appeared to remain in the tumour as the blood concentration fell over the time of the experiment, a phenomenon not reported previously with other antibodies. It is possible that the pattern of tumour uptake reflects antibody internalisation into the tumour cells and the subsequent retention of the macrocycle-chelated isotope. There was little or no accumulation of 90Y-A33 in nonspecific tissues emphasising the stability of the 9°Y-12N4 macrocycle complex reported previously (Harrison et al., 1991; DeNardo et al., 1994). Colon levels of activity were low. However, it should be remembered that any crossreaction with human colon would not be seen as the antibody is unlikely to cross-react with the equivalent mouse antigen. Immunohistochemistry studies have demonstrated some cross-reaction of A33 with normal human colon tissue, although clinical studies with radioiodinated A33 have not revealed any associated toxicity (Welt et al., 1994) . 90Y-TFM cleared much faster from the blood compared with IgG leading to lower tumour levels of 129+4.60% ID g-' obtained by 24 h after antibody injection. Again the tumour level remained high for a long period, only falling at 96 h despite almost complete removal of 9Y-TFM from the blood at this time. Among the normal tissues, kidney had the highest level of activity (6.40+0.45% ID g-' at 24 h), although this cleared much more rapidly than the tumour levels of activity. Accumulation did not occur in the kidney suggesting clearance through this organ. The route of clearance of TFM from the animal is not fully defined at present as we have not carried out full mass balance analysis of the injected material. However, we have carried out whole body clearance studies with TFM labelled with "'In, as these studies cannot be carried out with 90Y owing to absorption of the beta radiation by the body. These studies reveal that clearance from the whole body parallels that from the blood (P Antoniw et al., unpublished data), indicating that there is no deposition of activity in other tissues not examined in the biodistribution data presented.
The unexpectedly rapid blood clearance of TFM has recently been reported for another antibody, chimeric B72.3 labelled with 9Y using the same methodology (King et al., 1994) . These findings with A33 thus confirm that the normal tissue biodistribution pattern obtained is a consequence of the nature of the cross-linked antibody fragment, rather than a property of one individual antibody. The rapid blood clearance of TFM is of particular interest as it has the same molecular weight as IgG, and it may be that the Fc region which is lacking in TFM makes a contribution to the clearance pattern of IgG, Another possibility is that the nominal molecular weight cut-off for clearance of proteins through the kidney (Maack et al., 1979) is not reliant solely on size but also on other properties of the protein such as shape, flexibility or charge in a similar way to the effect on tumour penetration. The lack of high level accumulation of 90Y in the kidney is unusual for antibody fragments labelled with metallic isotopes and overcomes a previous limitation to radioimmunotherapy with such fragments (seen for example by Sharkey et al. 1990; Junghans et al., 1993) . Studies with a similar cross-linked antibody tri-Fab have also been reported by Schott et al. (1993) with '05Rh-labelled tri-Fab derived from the anti-TAG 72 antibody CC49. They also concluded that in vivo their tri-Fab had blood clearance properties intermediate between IgG and F(ab')2.
Although a very attractive nuclide for therapy, radioimmunotherapy using 90Y has previously been limited owing to the relatively poor chelators in use. Washburn et al. (1991) recorded colorectal carcinoma xenograft regression of approximately 40 days with 200 pCi 90Y-labelled CO17-lA.
A repeated dose of 150 ,uCi proved fatal to the mice. Prolongation of the survival of nude mice bearing colon carinoma xenografts by administration of 120 MCi of 9Y-ZCE025 (anti-CEA antibody) has also been reported (Hyams et al., 1989) . The median survival was doubled in comparison with the mice treated with the radiolabelled non-specific antibody. These LS174T tumours were grown intraperitoneally (i.p.) and the labelled antibody was also administered i.p. only 7 days after the cell inoculation. In the studies reported here with A33 the subcutaneous tumours were well established and growing before the 9Y-labelled antibody was administered i.v. and these tumours were eradicated with a single dose of either the IgG (250 ,uCi) or TFM (300 1iCi). Only a slightly higher dose of TFM was required, which was at the same time less toxic to the bone marrow than the IgG.
Interesting information was obtained from the histology of the subcutaneous sites of tumour implantation in mice cured with 9°Y-A33. The sites from the IgG-treated mice had small pockets of quiescent tumour cells visible among the necrotic and fibrotic areas. Examination of the sites from the two mice cured with 220 ,Ci of TFM however, demonstrated no tumour cells present. The rapid penetration of TFM in the tumour tissue which was demonstrated by autoradiography may play an important role in the cell killing activity considering that 90Y has a short half-life (64 h). Recent clinical data comparing "3'I-A5B7 IgG and F(ab')2 suggests that rapid penetration into the tumour can result in higher levels of activity localised to tumour for fragments compared with IgG (Lane et al., 1994) .
A number of reports have described delayed tumour growth and complete remission of solid tumour transplants by using various '31I-labelled monoclonal antibodies (Goldenberg et al., 1981; Cheung et al., 1986; Esteban et al., 1987; Senekowitsch et al., 1989; Blumenthal et al., 1989) . In most of these studies complete remission was only achieved when antibody treatment was administered within 24 h of tumour transplantation or by injecting a lethal amount of radiation. Attempts at experimental therapies have also been reported with '3'I-labelled fragments (Larson et al., 1983; Blumenthal et al., 1989; Buchegger et al., 1989; Pedley et al., 1993) .
Successful eradication of colon carcinoma xenografts in nude mice has been demonstrated with the use of "3'I-labelled F(ab')2 although a dose of 2200 puCi per mouse was required either as a single dose or fractionated over three administrations (Buchegger et al., 1989 (Buchegger et al., , 1990 .
Attempts at radioimmunotherapy with 90Y-labelled fragments have not previously been reported owing to the high levels of kidney accumulation seen with conventional Fab and F(ab')2 fragments (Sharkey et al., 1990) . Also, therapy with 90Y-macrocycle-labelled antibody has not been reported previously. Recently, therapy of 7-day-old xenografts has been demonstrated with the anti-TAG 72 antibody CC49 labelled with '77Lu via a similar macrocyclic ligand to that used for 90Y here (Schott et al., 1994) . Therapy studies with this relatively long lived isotope (half-life, 6.7 days) resulted in potent anti-tumour effects although severe toxicity was observed at the curative (500 ,uCi) dose with the death of 5/9 mice treated.
Here model is considered a reasonable estimate of the dose delivered to bone marrow. Thus, although TFM has a lower uptake of activity in the kidney than many antibody fragments (Sharkey et al., 1990) , it is likely that the doselimiting organ will be switched from bone marrow to kidney. Experience from external beam radiation therapy shows that kidney doses in excess of 1500 cGy result in a 5% complication probability. If one conservatively ignores the dose-rate effect then one may wish to limit the kidney dose to < 1500 cGy. Therefore, the maximum tolerated activity can be calculated as 1500/7.6 = 197 uCi, which would yield a maximum tumour dose of 2901 cGy with a blood dose of 473 cGy. Therapy with IgG on the other hand, would be limited by bone marrow toxicity. However, as bone marrow transplantation is now becoming more common to reduce the toxicity associated with radioimmunotherapy (Press et al., 1993) , it would theoretically be possible to increase the dose of IgG which could be administered. Without considering bone marrow toxicity, one could administer 333 iCi of IgG for the same level of kidney complications predicted with 197 pCi TFM, resulting in a tumoricidal dose of 16 900 cGy.
To improve therapy with TFM it would obviously be desirable to reduce kidney levels of activity further. Recently, strategies for reducing kidney accumulation of antibody fragments have been described, which suggest some further improvement may be possible (Behr et al., 1995) . Early attempts at cancer radioimmunotherapy in the clinic have met with only limited success. Clinical effects have been limited largely to radiosensitive and easily accessible tumours such as lymphoma with only limited benefit observed in colorectal cancer (Mach et al., 1991) . Several factors have limited more effective therapy including the penetration into the tumour mass, dose-limiting toxicity to the bone marrow and the inability to retreat owing to the generation of an immune response to the administered antibody. In this report we have attempted to address tumour penetration and the optimal form of the antibody for tumour accumulation with least toxicity to allow development of an effective radioimmunotherapeutic. We have also demonstrated the effectiveness of this agent in the mouse xenograft model system. Great care should be taken in the interpretation of mouse xenograft therapy studies owing to the well-known differences in therapeutic efficacy observed between mice and humans (Buchsbaum, 1995; Knox, 1995) . However, it seems likely that the benefits observed from stable chelation of 9Y and effective tumour penetration may result in improved prospects for clinical therapy.
Another major problem with radioimmunotherapy in man is the generation of a patient immune response to the administered murine antibody which prevents repeat treatments. To address this problem we have constructed humanised (CDR-grafted) versions of A33 and A33 TFM (King et al., 1995) which are currently being evaluated in clinical studies. Clinical studies with other antibodies have revealed that humanised antibodies do indeed reduce the immunogenicity of administered antibody (Stephens et al., 1995) and suggest that repeat therapy will be a realistic possibility.
